Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Qiagen ( (QGEN) ).
QIAGEN has disclosed a management transaction involving Thierry Bernard, a member of its managing body, following the implementation of a synthetic share repurchase program approved by shareholders at the 2025 Annual General Meeting. Under the terms of this program, every 20 issued QIAGEN shares were consolidated into 19, resulting in Bernard’s holdings being adjusted to 374,738 common shares, of which 108,570 are pledged under a securities lending transaction, reflecting the technical impact of the capital measure on insider shareholdings rather than a cash transaction.
The most recent analyst rating on (QGEN) stock is a Hold with a $48.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
QIAGEN N.V. is a life sciences and molecular diagnostics company headquartered in Venlo, Netherlands, with its shares listed on regulated markets in Frankfurt and multiple other European exchanges as well as on the NYSE and Swiss exchanges. The company focuses on providing sample and assay technologies for molecular testing in clinical, academic, pharmaceutical and biotech markets worldwide.
Average Trading Volume: 1,155,025
Technical Sentiment Signal: Strong Buy
Current Market Cap: $9.99B
For a thorough assessment of QGEN stock, go to TipRanks’ Stock Analysis page.